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Recent studies have shown that antioxidant enzyme expression and activity are drastically reduced in most human skin diseases,
leading to propagation of oxidative stress and continuous disease progression. However, antioxidants, an endogenous defense
systemagainstreactiveoxygenspecies(ROS),canbeinducedbyexogenoussources,resultinginprotectiveeﬀectsagainstassociated
oxidative injury. Many studies have shown that the induction of antioxidants is an eﬀective strategy to combat various disease
states. In one approach, a SOD mimetic was applied topically to mouse skin in the two-stage skin carcinogenesis model. This
method eﬀectively reduced oxidative injury and proliferation without interfering with apoptosis. In another approach, Protandim,
acombinationof5well-studiedmedicinalplants,wasgivenviadietaryadministrationandsigniﬁcantlydecreasedtumorincidence
and multiplicity by 33% and 57%, respectively. These studies suggest that alterations in antioxidant response may be a novel
approach to chemoprevention. This paper focuses on how regulation of antioxidant expression and activity can be modulated in
skin disease and the potential clinical implications of antioxidant-based therapies.
1.Introduction
Antioxidant enzyme expression is known to decrease with
aging, which has been theorized to contribute to age-related
diseases. One of the main contributors to disease progression
is reactive oxygen species (ROS) generation. ROS is the
result of incomplete reduction of oxygen within the electron
transport chain. The reactive oxidants of ROS include
superoxide anion (O
￿−
2 ), singlet oxygen (O2), hydrogen
peroxide (H2O2), and the hydroxyl radical (OH). Although
these molecules can act as signaling molecules, they can also
participate in cellular damage, such as lipid peroxidation and
DNA damage that trigger altered downstream signaling and
apoptotic pathways.
With skin being the largest, most readily exposed organ
to the environment, it is imperative that mechanisms of
protection against oxidative injury are in place within the
skin. The skin consists of various antioxidant enzymes such
as glutathione reductase, catalase, and superoxide dismutase.
These enzymes are often activated to maintain homeostasis
and to minimize the damaging eﬀects of ROS. However,
alterations in the expression/activity of these antioxidants
increase the susceptibility of skin to ROS-mediated injury
that contributes to skin disease. Many studies have shown
that antioxidant activity, mainly manganese superoxide dis-
mutase (MnSOD), is reduced in various skin cancers. For
example, epidermal SOD activity is decreased in hyperprol-
iferative keratinocytes in squamous cell carcinoma, basal cell
epithelioma, as well as benign hyperproliferative keratino-
cytes in the psoriatic epidermis [1–3]. This paper focuses on
the therapeutic potential of exogenous antioxidant inducers,
the use of SOD mimetics as a chemopreventive agent, and
dietary mechanisms of antioxidant induction in skin car-
cinogenesis.
2.M nSO DinSk inDisease
Psoriasis is a skin disease generally characterized by the
incomplete diﬀerentiation of epidermal keratinocytes, and
inﬁltration of leukocytes. Once localized within skin tissues,
these inﬂammatory cells release various cytokines and ROS
resulting in a high incidence of lipid peroxidation. Interest-
ingly, malondialdehyde, a key marker of lipid peroxidation,2 Enzyme Research
has been found at increased levels in the plasma and red
bloodcellsofpatientswithpsoriaticskin.Inaddition,plasma
levels of b-carotene and a-tocopherol levels were decreased,
along with decreased catalase and glutathione-peroxidase
activities in RBC, contributing to the pathogenesis of the dis-
ease. Lontz et al. examined the mRNA expression of MnSOD
in psoriatic skin tissue and found that MnSOD mRNA was
signiﬁcantly higher in lesional psoriatic skin compared to
nonlesional skin tissues [4]. Many postulated that associated
induction of MnSOD expression may serve as a protective
mechanism of increased survival; however, it was not found
to be directly correlated to disease pathogenesis. It is known
thatcytokinessuchasTNF-acaninduceMnSODexpression,
suggesting a direct correlation of increased MnSOD expres-
sion and the inﬂammatory mechanism of psoriasis. On the
other hand, the oxidative stress-mediated mechanism of
disease pathogenesis has been observed in other skin disease,
as well, such as contact dermatitis [5], acne, and vitiligo,
suggesting the need for further investigation of antioxidant-
based interventions in various skin diseases. In this quest,
MnSOD becomes a potential target, being that it is the ﬁrst
line of defense within skin tissues and when compared to
other SODs such as Cu, Zn-SOD, it is aﬀected diﬀerently in
variousskinabnormalities[6].Therefore,wewillcontinueto
further observe the induction, the role of overexpression and
chemopreventive potential of MnSOD in other skin diseases,
particularly skin carcinogenesis.
3. Induction of MnSOD Expression
MnSOD can be induced by a variety of stimuli including
cytokines [7, 8], radiation [9, 10], and chemical carcinogens
such as 12-O-tetradecanoylphorbol-3-acetate (TPA). Several
studies have shown that TPA can induce MnSOD expression;
by direct activation of protein kinase C (PKC) or through
the production reactive oxygen species that can act as cell
signaling molecules activating redox-sensitive transcription
factors such as AP-1 and NF-κB[ 11–13]. However, several
studies have shown that MnSOD expression is reduced in
most human cancers. It has been found that the reduction
in MnSOD expression is not due to defects in the primary
structure of the MnSOD protein, but rather changes in
gene expression [14, 15]. Several transcription factors have
been implicated in the induction of MnSOD expression;
however, the most widely studied is speciﬁcity protein 1
(Sp1). The transcription factor Sp1 contains three zinc ﬁnger
motifs in the DNA-binding domains that recognize GC-rich
sequences of GGGCGG [16]. The GC-rich characteristics of
the MnSOD promoter are conserved among mouse [17],
bovine [18], rat [19], and human [20]. The Sp1 protein is
capable of inducing gene expression by forming homotypic,
Sp1-Sp1interactions[21–23].However,SP-1bindingaﬃnity
and transcription properties can be altered by interactions
with other cofactors. Sp1 forms heterotypic interactions
with diﬀerent classes of nuclear proteins such as TATA box-
binding protein (TBP) [24], C/EBP [25], and YY1 [26, 27].
SP-1 recognition sequences are often found to be near
binding sites for othertranscription factors such as AP-1
[28], AP-2 [29], and even NF-κB[ 30] suggesting that SP-
1 may work in conjunction with other transcription factors
to modulate MnSOD gene expression. On the other hand,
studies have shown that subcellular organelles, such as the
mitochondria can regulate the induction of antioxidant
g e n e ss u c ha ssod2. Kim et al. showed that in an eﬀort to
maintain an optimal mitochondrial redox state, increased
MnSOD expression led to endogenous sod2 transcripts,
and increased sod2 mRNA levels were a result of increased
transcriptional activation of the sod2 gene in mice [31]. In
addition, it is known that homozygous sod2−/− knockout
mice exhibit a neonatal lethality phenotype that is not
reversed or delayed by copper/zinc superoxide dismutase
or sod1 overexpression [32]. Therefore, maintenance of the
cellular redox state and induction of MnSOD expression is
important to cell viability.
4. Mechanisms of Action of MnSOD
Initially, it was postulated that ﬂavones and antioxi-
dants inhibit skin carcinogenesis by interfering with the
metabolismofcarcinogensintotheultimatecarcinogenform
[33, 34]. Several studies have found that overexpression as
well as deﬁciencies in MnSOD expression can have signif-
icant eﬀects on tumor formation using this two-stage skin
carcinogenesis model. Skin carcinogenesis is known to occur
in a two-stage process. The two-stage skin carcinogenesis
model is a well-established model utilized to study the
multiple stages of skin carcinogenesis: tumor initiation, pro-
motion, and metastasis. A single application of the polycyclic
aromatic hydrocarbon, 7, 12-dimethylbenz[a]anthracene, is
applied at a subthreshold dose. Chemical mutagens, such as
DMBA are known to induce carcinogen-speciﬁc mutations
in the H-ras gene at codon 61 [35, 36]. Mutations in the H-
ras gene confer a selective advantage within H-ras initiated
cells, which can develop into benign tumors after treatment
with tumor-promoting agents such as TPA [37]. Following
this subcarcinogenic dose, multiple applications of TPA are
applied to induce epigenetic changes. The tumor promotion
stage is essentially reversible; however, later in the tumorige-
nesis process, this stage becomes irreversible. Overall, tumor
promotion inhibitors have common mechanisms of action:
(1) altered metabolism of the carcinogen, (2) scavenging
abilities of active molecular species of carcinogens, and lastly
(3) competitive inhibition [38] .S e v e r a ls t u d i e sh a v es h o w n
the inverse relationship of ROS and MnSOD expression
in the pathogenesis of hyperproliferative and inﬂammatory
diseases. It is known that DMBA/TPA treatment induces cell
proliferation and apoptosis; both believed to be modulated
by oxidative stress propagation [39]. For example, it was
found that overexpression of MnSOD, in the two-stage
skin carcinogenesis mouse model, reduced the number and
incidence of papillomas providing direct evidence of free
radical involvement in skin carcinogenesis [40]. Zhao et al.
showed that apoptosis preceded cell proliferation [39]. It
was found that apoptosis peaked at the 6-hour time point,
prior to the peak in cell proliferation at 24h [39]. Pro-
viding a therapeutic window for antioxidant intervention,Enzyme Research 3
MnTE-2-PyP5+, a small molecule catalytic antioxidant (SOD
mimetic), was applied following the peak in apoptosis. It was
found that papilloma formation decreased 6-fold compared
to their control counterparts, without eﬀecting apoptosis.
These results suggest that antioxidant therapy is an eﬀective
mode of tumor suppression and can potential be used
in conjunction with traditional chemotherapeutics without
interfering with drug-induced cell death. Consistent with
that, it was found that in the presence of MnTE-2-Pyp5+, the
level of oxidative injury was signiﬁcantly reduced. Therefore,
these results suggest the oxidative stress-mediated tumor
promotion of TPA, as well as, the antioxidant capabilities
of MnSOD in tumor suppression. Furthermore, in a study
usingMnSODtransgenicmice,itwasfoundthatonly50%of
transgenic mice developed papillomas, compared to 78% of
their nontransgenic counterparts [40]. These results, again,
suggest the antioxidant capabilities of MnSOD as a tumor
suppressor.
Moreover, superoxide anions, one of the major con-
stituents of ROS, act as signaling molecules that can regulate
oncoproteins and downstream gene expression. As a key
cellularredoxregulator,MnSODhasbeenshowntoaﬀectthe
binding activities of transcription factors to transcriptional
control elements, therefore modulating gene expression. The
mechanism behind MnSOD mediated tumor suppression
has been shown to involve suppression of activator protein-1
(AP-1)activity.AP-1isakeymediatorofoncogenicsignaling
[37]. There are many posttranslational modiﬁcations that
can regulate AP-1 activity such as modulation of the
phosphorylation states of the Jun or Fos protein [41]a n d
redox regulation of the Jun protein. High levels of phospho-
rylated c-Jun, Fra-1, Fra-2, and ATF-2 proteins have been
shown to positively correlate with malignant phenotypes
in the multistage mouse skin carcinogenesis model [37].
In addition, the increased expression and posttranslational
modiﬁcations of these oncoproteins account for a high
percentage of the increased AP-1 activity. In malignant cell
lines, the DNA binding and transactivation properties of AP-
1 have been found to be elevated, peaking in fully metastatic
cell lines [37]. The transcription factor, AP-1, is known
to play a role in cellular diﬀerentiation, proliferation, and
transformation. The AP-1 complex is known to consist of
the homo- or heterodimer of the Fos, Jun, and Fra family
members. Many of the subunits of AP-1 are redox sensitive
and can be regulated by posttranslational modiﬁcations
induced by TPA-mediated ROS signaling. It is known that
AP-1 activation can be detected as soon as 6 hours post-
TPA treatment. Zhao et al. showed that by overexpressing
MnSOD in human MnSOD transgenic mice, the initial
activation of AP-1 was delayed and resulted in a signiﬁcant
reduction in papilloma formation [40]. When both non-
transgenic and MnSOD transgenic mice were treated with
DMBA/TPA, it was shown that JunD was the only family
member whose expression was increased within 24h of TPA
treatment [40]. Another kinase found to be involved in AP-
1 activity is c-Jun N-terminal kinase (JNK). JNK activity has
beenshowntoincreasemorethanthreefoldinmalignantcell
lines [37]. It was found that the increased phosphorylated
formofJNKseenat6hpost-TPAtreatmentinnontransgenic
mice was delayed and reduced in MnSOD transgenic mice
24h post TPA treatment. These results therefore suggest
that MnSOD overexpression can aﬀect TPA-induced AP-1
activation by modulating JNK kinase activity. Nevertheless,
wehaveshownthattheinductionofendogenousantioxidant
enzymes, particularly MnSOD, is eﬃcient in reducing tumor
incidence, as well as, mediators of proliferation [40].
5. Overexpression of MnSOD
As mentioned previously, overexpression of MnSOD has
been shown to be anticarcinogenic in the two-stage skin
carcinogenesis model. Overexpression of MnSOD not only
reduced tumor multiplicity and incidence, but also mod-
ulated cell proliferative pathways such as AP-1signaling
and DNA binding activity. In a large number of in vitro
and in vivo models, and in even in gene-radiotherapy,
MnSOD overexpression has been shown to suppress the
malignant phenotype and metastatic ability of tumor cells.
MnSOD is an attractive therapeutic target because of its
high inducibility and subcellular mitochondrial localization.
While various physiological stimuli have been shown to
induce MnSOD expression such as cytokines, oxidative
stress, and growth factors, the main function of MnSOD
is to protect mitochondrial DNA from oxidative injury.
Mitochondria are known as the powerhouse of the cell. Not
only is mitochondria one of the main energy-generating
organelles of the cell, but it is also considered one of the
main generators of ROS. Oxygen radicals cannot only act as
signaling molecules, but can also promote cell death, which
is mainly mediated through the mitochondria. It is known
that ROS can amplify the apoptotic cascade by expediting
the release of mitochondrial cytochrome c via mitochondrial
oxidative damage [42]. With MnSOD being an eﬀective reg-
ulator of cellular redox status, this endogenous antioxidant
enzyme can also provide cytoprotection from ROS-mediated
apoptosis. However, the complexity of MnSOD expression
and its involvement cancer progression still remains elusive.
Zhao et al., in 2002, showed that a deﬁciency in MnSOD
expressioninMnSODheterozygousknockout(MnSODKO)
mice enhanced cell proliferative signaling [42]. As previously
mentioned, AP-1 signaling was suppressed via MnSOD
overexpression. Surprisingly, the number of apoptotic cells
increased as well, suggesting that MnSOD expression may
notonlyplayaroleintumorsuppression,butmaycontribute
to cell survival. MnSOD expression has been shown to
be increased in various malignancies including human
cervical carcinoma [43], brain malignant tumors [44], lung
[45], gastric and colon cancers [46]. Consistent with that,
in vitro experiments have shown that overexpression of
MnSOD protects cells from ionizing radiation and in some
cases induces resistance to chemotherapeutic drugs such as
adriamycin [47]. Many investigators suggest that the survival
mechanisms of MnSOD are mediated by hydrogen peroxide
(H2O2) generation that overwhelms the cell capacity to
regulate H2O2 accumulation, promoting cell survival and
proliferative signaling. Nevertheless, further studies are
needed to elucidate the H2O2-mediated mechanism.4 Enzyme Research
6.M nSO DinDisease:Sk inCanc e r
Enzymatic inactivation is known to be associated with most
pathological states of disease. With various mechanisms of
inactivation, determining the mechanism of inactivation
can be complex. Consistent with that, determining the
beneﬁts/damaging contributions of MnSOD is controversial,
particularly in diseases such as skin carcinogenesis. There-
fore, further investigation of activity/expression modulation
in various disease states is needed to identify potential
therapeutic targets. Previous studies from our lab have
shown that ROS generation is increased in the early stages
of skin carcinogenesis. It was found that NADPH oxidase
was a key contributor to oxidative stress propagation in the
DMBA/TPA two-stage skin carcinogenesis model. However,
further studies showed that oxidative stress propagation
induced p53 mitochondrial translocation. In our in vitro
studies, skin epidermal JB6 P+ cells were treated with
TPA, 10 minutes post-TPA treatment, the tumor suppressor
p53, monitored by immunoﬂuorescence staining, rapidly
translocated to the mitochondria. Utilizing immunogold
labeling, p53 was found localized on the outer membrane,
and surprisingly in the mitochondrial matrix. With both
MnSOD and p53 mitochondrial localization being key
elements in cell fate, it was found via immunoprecipita-
tion that mitochondrial p53 interacts with MnSOD within
the mitochondria. Currently, there is growing controversy
surrounding MnSOD’s involvement in disease and most
importantly the state of MnSOD expression, as well as its
activity.Interestingly,followingthep53-MnSODinteraction,
MnSOD protein levels increased by 60%, whereas its activity
decreased 11%, suggesting that MnSOD activity levels may
play a more signiﬁcant role in disease rather than expression.
Subsequently following the reduction in MnSOD activity,
the transcriptional activity of nuclear p53 was increased 1-
hour post-TPA treatment, represented by an increase in the
proapoptotic protein Bax, a transcriptional target of p53. In
addition, the increase in p53 activation was associated with
an increase in DNA fragmentation and apoptotic cell death.
However, when treated with the MnSOD mimetic, MnTE-
PyP5+, mitochondrial p53 levels were slightly reduced, and
p53 nuclear translocation and transactivation was com-
pletely blocked. Previous studies showed that TPA induced
both cell proliferation and p53-mediated apoptosis. How-
ever, the involvement of MnSOD modulation in this process
remainedunsolved.Theresultsfromthisstudyprovidealink
between mitochondrial redox status and nuclear regulation
of apoptotic signaling and cell survival.
7. MnSOD As a Chemopreventive Agent
MnSOD is a highly inducible enzyme important to cell
viability, but can also modulate cell proliferation and
apoptotic signaling. Our lab utilized these mechanisms of
action as a chemopreventive modality in skin carcinogenesis.
Protandim, a dietary supplement consisting of 5 well-
established medicinal plant extracts, has received increasing
attention for itstherapeutic eﬀects in various disease
pathologies [47–49]. Protandim consists of B. monnieri
(45% bacosides), 150mg; S. marianum (70–80% silymarin),
225mg; W. somnifera (1.5% withanolides), 150mg; C.
sinensis (98% polyphenols and 45% (−)-epigallocatechin-
3-gallate), 75mg. [50]. Antioxidants have known anticancer
eﬀects. However, several large clinical trials using small
molecule antioxidants have failed, which poses several
questions: Do antioxidant-based therapies contribute to
disease progression by becoming prooxidants themselves?
Are antioxidant-based therapies potent enough to overcome
the ROS-generating load of various disease states? In general,
cancer cells have a higher ROS generation status than
normal cells. As a result, a number of antioxidant enzymes
are signiﬁcantly reduced in expression levels and activity. In
addition, polymorphisms in MnSOD have been shown to be
associated with a higher risk of prostate, breast, and other
various cancers. However, MnSOD is the only antioxidant
enzyme shown, when overexpressed, to reduce multicancer
cell growth both in vitro and in vivo [51]. In other studies,
small molecule catalytic antioxidant enzymes have been
shown to be a more potent and practical approach for cancer
chemoprevention. Sporn and Suh deﬁne chemoprevention
as a pharmacological approach to intervention in order to
arrest or reverse the process of carcinogenesis [52]. In our
study, the two-stage mouse skin carcinogenesis model was
used to investigate the mechanisms of action of Protandim
during the early stages of skin carcinogenesis. Overall, the
process of carcinogenesis is mediated by ROS generation and
the ability of oxygen radicals to act as signaling molecules to
modulate downstream carcinogenic events. We have found
that the positive feedback loop that is formed by oxidative
stress, cell proliferation and p53-mediated apoptosis plays
a major role in contributing to carcinogenesis. Thus, it was
postulated that the induction of MnSOD via Protandim
couldbreakthispositivefeedbackcycleleadingtocancerpre-
vention. Mice utilized in this study were fed the Protandim
diet during the tumor promotion stage (i.e., 2 weeks follow-
ing DMBA initiation and 2 weeks prior to TPA treatment
and for the duration of the study). Overall, no tumors were
formed in the vehicle control/basal diet groups. However,
both tumor incidence and multiplicity were reduced by 33%
and 57%, respectively, in the Protandim diet group [53].
These results suggest that modulation of oxidative stress
through the induction of antioxidant enzymes via dietary
administration is suﬃcient in reducing tumor formation.
Nonetheless, oxidative stress alters both gene expression
and cancer biology. Another key component of tumor
progression is inﬂammation. Within the tumor microen-
vironment, various inﬂammatory cells release ROS and
other inﬂammatory mediators. Tumors often utilize these
pro-inﬂammatory mediators to foster cell proliferation,
angiogenesis and metastasis [54]. Utilizing the two-stage
model, we found that dietary administration of Protandim
signiﬁcantly decreased TPA-mediated macrophage inﬁltra-
tion, as well as, pro-inﬂammatory signaling pathways. For
example, nuclear factor kappa B (NF-κB), a central reg-
ulator of immunity and inﬂammation, is a transcription
factor of biological interest because of its sensitivity to the
intracellular redox status. NF-κB regulates the expressionEnzyme Research 5
of numerous genes that encode selectins, cytokines, and
cellular adhesion molecules. Oxidative stress generation is
known to induce NF-κB nuclear translocation. Intracellular
adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) are transcriptionally regulated by
NF-κB. Skin tissues from mice fed the Protandim diet
exhibited reduced NF-κB DNA binding activity, resulting in
a reduction in the protein expression levels of both cellular
adhesion molecules. Therefore, these results suggest that
Protandim not only suppresses tumor formation, but also
mechanistically modulates pro-inﬂammatory signaling and
the immune response via gene transcription.
Asmentionedpreviously,p53interactswithMnSODfol-
lowing TPA-mediated oxidative stress generation. Therefore,
is it possible for a dietary-mediated induction of MnSOD
expression/activity to modulate p53 mitochondrial translo-
cation and accompanying apoptosis? Skin tissues from
DMBA/TPA treated mice were analyzed to assess the eﬀects
of the Protandim diet on p53 mitochondrial translocation
[55]. Interestingly, skin tissues from Protandim-fed mice
showed a signiﬁcant decrease in mitochondrial p53 protein
expression. Consistent with that, the number of apoptotic
cells was also signiﬁcantly decreased. Thus, the induc-
tion of antioxidant enzymes via dietary administration of
Protandim modulates both TPA-mediated cell proliferation
and p53-mediated apoptotic signaling. Therefore, it can be
concluded that oxidative stress forms a mechanistic linkage
between cell proliferation, inﬂammation, and apoptosis,
suggesting that potent multimodal antioxidant inducers may
potentially be utilized with conventional chemotherapeutics.
8. Conclusion
For many decades, ROS generation has been known to
not only cause oxidative injury, but also act as signaling
molecules that regulate cell proliferation and downstream
gene expression. However, the induction of MnSOD is
gaining interest as an eﬀective novel mechanism of chemo-
prevention, being that it is the only antioxidant enzyme that
when overexpressed suppresses tumor formation. MnSOD
also has the ability to modulate multiple pathways contribut-
ing to skin carcinogenesis. Continuous eﬀorts are currently
being made to develop compounds that eﬀectively induce
MnSODin hopes to incorporate antioxidant-based therapies
into current clinical practice. Therefore, the development of
various MnSOD inducers to be used during the early-onset
of tumorigenesis may be a plausible modality utilized to
suppressunderlyingmechanismsinvolvedincarcinogenesis.
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